Differences in the biologic activity of 2 novel MEK inhibitors revealed by18F-FDG PET: Analysis of imaging data from 2 phase I trials

Journal of Nuclear Medicine

Volumn 53, Issue 12, 2012, Pages 1836-1846

  Kraeber Bodéré, Françoise ^a   Carlier, Thomas ^a   Naegelen, Valérie Meresse ^b   Shochat, Eliezer ^b   Lumbroso, Jean ^c   Trampal, Carlos ^d   Nagarajah, James ^e   Chua, Sue ^f   Hugonnet, Florent ^g   Stokkel, Marcel ^h   Gleeson, Fergus ⁱ   Tessier, Jean ^b  

^a Team 12   (France)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d Image Processing Department   (Spain)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g INSTITUT CURIE   (France)

^h NETHERLANDS CANCER INSTITUTE   (Netherlands)

ⁱ CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

18F FDG PET; Biomarker; MEK inhibitor

Indexed keywords

3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO) N (2 HYDROXYETHOXY) 5 [(3 OXO 1,2 OXAZINAN 2 YL)METHYL]BENZAMIDE; FLUORODEOXYGLUCOSE F 18; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; RO 5126766; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COLON CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG INTERMITTENT THERAPY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; IMAGE ANALYSIS; INHIBITION KINETICS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MELANOMA; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RECTUM CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; BENZAMIDES; CLINICAL TRIALS, PHASE I AS TOPIC; COUMARINS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASMS; OXAZINES; PHOSPHOPROTEINS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; TREATMENT FAILURE; YOUNG ADULT;

EID: 84870442338     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.109421     Document Type: Article

References (24)

1. Boss DS, Olmos RV, Sinaasappel M, Beijnen JH, Schellens JH. Application of PET/CT in the development of novel anticancer drugs. Oncologist. 2008;13:25-38. (Pubitemid 351206694)
2. van Dongen GA, Poot AJ, Vugts DJ. PET imaging with radiolabled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumour Biol. 2012;33:607-615.
3. Saleem A, Ranson M, Callies S, et al. Microdosing imaging pharmacokinetic (PK) study of the antisense oligonucleotide (ASO) to survivin (LY2181308) using positron emission tomography (PET): a novel paradigm in clinical drug development [abstract]. J Clin Oncol. 2009;27:15S.
4. Facey K, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess. 2007;11:iii-iv, xi-267.
5. Van den Abbeele AD. The lessons of GIST-PET and PET/CT: a new paradigm for imaging. Oncologist. 2008;13(suppl 2):8-13.
6. Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer. 2009;115:616-623.
7. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26:3279-3290. (Pubitemid 46763021)
8. Dolly SO, Albanell J, Kraeber-Bodere F, et al. First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors [abstract]. J Clin Oncol. 2011;29(15 suppl):3006.
9. Leijen S, Middleton MR, Tresca P, et al. Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced/metastatic solid tumor [abstract]. J Clin Oncol. 2011;29 (15 suppl):3017.
10. 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006;47:1059-1066.
11. Vanderhoek M, Perlman SB, Jeraj R. Impact of the definition of peak standardized uptake value on quantification of treatment response. J Nucl Med. 2012;53:4-11.
12. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-1782.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
14. Milano A, Perri F, Ciarmiello A, Caponigro F. Targeted-therapy and imaging response: a new paradigm for clinical evaluation? Rev Recent Clin Trials. 2011;6:259-265.
15. 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies. J Nucl Med. 2009;50:1646-1654.
16. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(suppl 1):122S-150S.
17. Kefford R, Arkenau H, Brown MP, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors [abstract]. J Clin Oncol. 2010;28(15 suppl):8503.
18. McArthur G, Puzanov I, Ribas A, et al. Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma [abstract]. J Clin Oncol. 2010;28(15 suppl):8529.
19. Ross RW, Manola J, Oh WK, et al. Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity. J Clin Oncol. 2008;26 (15S):5069.
20. Kawada K, Murakami K, Sato T, et al. Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors. Jpn J Clin Oncol. 2007;37:44-48. (Pubitemid 47090722)
21. Infante JR, Fecher LA, Nallapareddy S, et al. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212 [abstract]. J Clin Oncol. 2010;28(15 suppl):2503.
22. Shapiro G, LoRusso P, Kwak EL, et al. Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: a first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors [abstract]. J Clin Oncol. 2011;29(15 suppl):3005.
23. 18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Cancer Res. 2007;67:11463-11469.
24. Leyton J, Smith G, Lees M, et al. Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. Mol Cancer Ther. 2008;7:3112-3121.